ArticleDiabetology & metabolic syndrome2020
Relationship of metabolic syndrome defined by IDF or revised NCEP ATP III with glycemic control among Malaysians with Type 2 Diabetes.
Article in Diabetology & metabolic syndrome, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Impact of MIND diet on cognitive function among patients with metabolic syndrome: a randomised control clinical trial.BMC neurology · 2026Trial
- Ethnic and Gender Disparities in Risk Factors for Prediabetes-A Retrospective Exploratory Analysis in Southern Israel.Journal of clinical medicine · 2026Article
- Article
- Association of 25-hydroxyvitamin D and chemerin with metabolic syndrome components in individuals with type 2 diabetes mellitus.Frontiers in medicine · 2026Article
- Trends in the prevalence of metabolic syndrome among Jordanian adults following COVID-19.Therapeutic advances in endocrinology and metabolism · 2026Article
- The association between dietary protein intake and metabolic syndrome: a GRADE-assessed systematic review and meta-analysis of observational studies.Diabetology & metabolic syndrome · 2025Review
- Effects of Propolis Supplementation on Metabolic Syndrome Indices, Isfahan, Iran, 2023: A Randomized Controlled Clinical Trial.Health science reports · 2025Article
- Association between morphological and mechanical properties of lower limb muscles and metabolic syndrome in type 2 diabetes.Diabetology & metabolic syndrome · 2025Article
- Relative Excess Risk of Metabolic Syndrome Due to Interaction Between Handgrip Strength and Dietary Patterns Among Korean Youth.Nutrients · 2025Article
- Article
- KLF14 and SREBF-1 Binding Site Associations with Orphan Receptor Promoters in Metabolic Syndrome.International journal of molecular sciences · 2025Article
- The interplay of factors in metabolic syndrome: understanding its roots and complexity.Molecular medicine (Cambridge, Mass.) · 2024Review
- The effects of MIND diet and propolis supplementation on metabolic syndrome: A randomized controlled clinical trial.Heliyon · 2024Article
- Review
- Review
- Inflammatory biomarkers link perceived stress with metabolic dysregulation.Brain, behavior, & immunity - health · 2023Article
- Non-HDL cholesterol and long-term follow-up outcomes in patients with metabolic syndrome.Lipids in health and disease · 2023Article
- Abdominal obesity, serum estradiol and cardiovascular risk among Nigerian postmenopausal women: a cross-sectional study.African health sciences · 2023Article
- A Role for Fatty Acids in Peripheral Neuropathy Associated with Type 2 Diabetes and Prediabetes.Antioxidants & redox signaling · 2022Review
- The potential role of miR-27a and miR-320a in metabolic syndrome in obese Egyptian females.Journal, genetic engineering & biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe chronic complications of Type 2 Diabetes (T2D) such as macrovascular disease is amplified with the increase in the number of metabolic syndrome (MetS) risk factors. This research aims to study the relationship of MetS, diagnosed by the International Diabetes Federation (IDF) or revised National Cholesterol Education Programs Adult Treatment Panel III (NCEP ATP III) criteria, with glycemic control, fasting blood glucose (FBG), glycated hemoglobin (HbA1c), C-peptide, and insulin resistance in T2D patients.
methodsThe study is a cross-sectional observational study which, involved 485 T2D patients who are receiving treatment at the University Kebangsaan Malaysia Medical Center (UKMMC), Kuala Lumpur, Malaysia. The MetS among the T2D patients was diagnosed based on IDF and revised NCEP ATP III criteria. C-peptide and HbA1c levels were determined by an automated quantitative immunoassay analyzer and high-performance liquid chromatography, respectively. The MetS factors; FBG, triglyceride, and high-density lipoprotein cholesterol were measured by spectrophotometer.
resultsApplication of the IDF and revised NCEP ATP III criteria respectively resulted in 73% and 85% of the T2D subjects being diagnosed with MetS. The concordance of these criteria in diagnosing MetS among T2D patients was low (κ = 0.33,
conclusionAlthough there is a low concordance between IDF and revised NCEP ATP III criteria in the diagnosis of MetS among T2D patients, both criteria showed that T2D patients with 5 MetS factors had higher insulin resistance, C-peptide, FBG, and HbA1c.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.